Fasting Comparative Bioavailability Study of 2 Meloxicam 15 mg Tablets in Healthy Volunteers Under Fasting Condition

Randomized, Single-dose, Crossover, Two-period, Two-sequence, Laboratory-blinded, Comparative Bioavailability Study of Meloxicam 15 mg Tablets in Healthy Volunteers Under Fasting Condition.

The aim of the study was to compare the bioavailability of two formulations of meloxicam given to healthy volunteers and to demonstrate bioequivalence. The test product, Reumoxicam® 15 mg tablets (Farmak PJSC, Ukraine), given in a single dose was compared with a licensed reference product Movalis 15 mg tablets ("Boehringer Ingelheim Ellas A.E.", Greece), in a randomized, laboratory-blind, single dose, two periods, crossover study.

The secondary objective of the trial was to investigate the safety of both preparations on the basis of safety clinical and laboratory examinations (at the beginning and at the end of the trial) and registration of adverse events and/ or adverse drug reactions.

Study Overview

• Status: Completed
• Conditions: Pharmacokinetics
• Intervention / Treatment: Drug: Reumoxicam® 15 mg tablets (PJSC "Farmak", Ukraine); Drug: Movalis 15 mg tablets ("Boehringer Ingelheim Ellas A.E.", Greece)

Detailed Description

Randomized, single-dose, crossover, two-period, two-sequence, laboratory-blinded, comparative bioavailability study of test medicinal product Reumoxicam® 15 mg tablets (PJSC "Farmak", Ukraine) and reference medicinal product Movalis 15 mg tablets ("Boehringer Ingelheim Ellas A.E.", Greece) in healthy volunteers under fasting condition.

During each period 18 blood samples were taken: before dosing (0) and then at: 0.5; 1; 2; 3; 4; 4.5; 5; 5.5; 6; 7; 8; 10; 12; 24; 36; 48 and 72 hours after dosing.

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Phase 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Healthy volunteers, men and women aged 18 to 45 years (inclusive);
2. Provided written Informed Consent Form of a Healthy Volunteer for Participation in the Clinical Study before the beginning of any screening procedures;
3. Ability (to the opinion of the investigator) to fulfill all requirements of the Study Protocol, i.e. the volunteer's ability for adequate collaboration;
4. Body mass index is within the limits (> 18,5 kg/m2 and < 30,0 kg/m2);
5. Persons free from any acute and chronic diseases of cardiovascular system, neuroendocrine system, kidneys, liver, gastrointestinal tract, and respiratory system;
6. Results of physical, instrumental, and laboratory examination of volunteers are within the normal limits, or any deviations are classified by the investigator as clinically irrelevant;
7. Chest fluorography or radiography results are within the normal limits (the examination should be carried out no earlier than 9 months before the screening moment), or any deviation is classified by the investigator as clinically irrelevant;
8. Women and men have to use medically confirmed barrier method of contraception during the whole study period;
9. Volunteers have to be non-smokers or smoke up to 10 cigarettes a day inclusive;
10. Volunteers need to undertake to follow all general diet limitations during the whole study period.

Exclusion Criteria:

1. Subjects with evidence or suspicion of any relevant clinical abnormality (as based on medical history, physical examination, vital signs, chest X-ray, and 12-lead ECG)
2. Known hypersensitivity to meloxicam and/or other investigational products ingredients;
3. Compromised allergologic history;
4. Subjects who have developed signs of asthma, nasal polyps, angio-oedema or urticaria following the administration of aspirin or other NSAIDs;
5. Active peptic ulcer, gastrointestinal perforation or bleeding within the last 6 months;
6. Subjects with peripheral oedema;
7. Any previously incurred diseases or surgical interventions which, to the investigator's opinion, may affect pharmacokinetics of the investigational product;
8. Positive result of HIV, syphilis, hepatitis B and C markets test;
9. Positive result of urine test for narcotic substances (amphetamine, metamphetamine, morphine, marijuana, cocaine);
10. Positive result of alcohol vapors test in expired air;
11. Pregnancy (positive result of urine pregnancy test in women) and lactation period;
12. Incurred acute infectious diseases within 28 days before beginning of the study;
13. Use of any medicinal products within 14 days before beginning of the study;
14. Blood donation or blood loss of more than 300 ml in less than 30 days before beginning of the study;
15. Participation in any other clinical study during the last 90 days before beginning of the study;
16. Other reasons which, to the investigator's opinion, make the volunteer's participation in the study undesirable.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: OTHER
• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Treatment A; Reumoxicam® 15 mg tablets (PJSC "Farmak", Ukraine)	Drug: Reumoxicam® 15 mg tablets (PJSC "Farmak", Ukraine); One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.; Other Names: Meloxicam
ACTIVE_COMPARATOR: Treatment B; Movalis 15 mg tablets ("Boehringer Ingelheim Ellas A.E.", Greece)	Drug: Movalis 15 mg tablets ("Boehringer Ingelheim Ellas A.E.", Greece); One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.; Other Names: Meloxicam

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUC0-t	Area under the plasma concentration-time curve from time zero to time t of the last quantifiable concentration	up to 72 hours post-administration
Cmax	Maximum drug concentration in plasma	up to 72 hours post-administration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUC0-inf	Area under the plasma concentration-time curve from time zero to infinity	up to 72 hours post-administration
tmax	time after administration to reach maximum drug concentration in plasma	up to 72 hours post-administration
t1/2	elimination half-life	up to 72 hours post-administration

Collaborators and Investigators

• Sponsor: Joint Stock Company "Farmak"

Study record dates

Study Major Dates

• Study Start (ACTUAL): January 29, 2014
• Primary Completion (ACTUAL): February 26, 2014
• Study Completion (ACTUAL): February 26, 2014

Study Registration Dates

• First Submitted: November 15, 2021
• First Submitted That Met QC Criteria: November 17, 2021
• First Posted (ACTUAL): November 18, 2021

Study Record Updates

• Last Update Posted (ACTUAL): November 18, 2021
• Last Update Submitted That Met QC Criteria: November 17, 2021
• Last Verified: November 1, 2021

More Information

Terms related to this study

• Keywords: pharmacokinetics; bioequivalence; Meloxicam; generic drugs
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Cyclooxygenase Inhibitors; Cyclooxygenase 2 Inhibitors; Meloxicam
• Other Study ID Numbers: FM-MEL

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No